

Mona Munteanu

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9344197/mona-munteanu-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

14
papers

848
citations

8
h-index

14
g-index

14
ext. papers

957
ext. citations

3.9
avg, IF

2.64
L-index

#	Paper	IF	Citations
14	Consequences of Extended Spectrum Beta-Lactamase-Producing Enterobacteriaceae and Methicillin-Resistant Staphylococcus aureus Carriage in Awaiting Liver Transplant Patients. <i>Liver Transplantation</i> , 2021 , 27, 43-54	4.5	0
13	Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 32, 998-1007	2.2	5
12	Identification of an Endoglin Variant Associated With HCV-Related Liver Fibrosis Progression by Next-Generation Sequencing. <i>Frontiers in Genetics</i> , 2019 , 10, 1024	4.5	6
11	The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019 , 31, 393-402	2.2	8
10	LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 308-320	6.1	8
9	Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 569-577 ²		13
8	Impact of steatosis and inflammation definitions on the performance of NASH tests. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 384-391	2.2	7
7	Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 1117-1127	6.1	14
6	Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. <i>Gastroenterology</i> , 2012 , 143, 1244-1252.e12	13.3	111
5	Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. <i>PLoS ONE</i> , 2012 , 7, e30325	3.7	95
4	FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC program. <i>Journal of Hepatology</i> , 2011 , 54, 227-35	13.4	16
3	Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age. <i>BMC Gastroenterology</i> , 2011 , 11, 39	3	53
2	Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. <i>Clinical Chemistry</i> , 2007 , 53, 1615-22	5.5	208
1	Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2006 , 6, 6	3	304